RecruitingNot Applicable

EndoPAT Device for Endothelial Dysfunction in ED

United States120 participantsStarted 2025-08-13

Plain-language summary

To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound. To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy. To investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testosterone (T) therapy

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males 18 years old and above * Diagnosed with erectile dysfunction or hypogonadism Exclusion Criteria: * Patients without the above criteria

What they're measuring

Endothelial Function as Measured by Reactive Hyperemia Index (RHI)

Timeframe: At baseline, 3 months, and 6 months post-intervention

Trial details

NCT IDNCT06720597

SponsorUniversity of California, Irvine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-01

Contact for this trial

Muhammed AM Hammad, MBBCh

714-456-7005 mahammad@hs.uci.edu

View on ClinicalTrials.gov More Erectile Dysfunction trials